Search PubMed⌕ Search

Biomedical subjects

M Gobbi

Publications and source records attributed to M Gobbi.

At least 253 records · Page 14Linked to original sources
PubMedDate not supplied

T lymphocyte subsets and colony growth in hairy-cell leukemia.

The distribution of T cell subsets and the T colony-forming capacity were assessed in 22 patients with hairy-cell leukemia. An overall increase in the proportion of T gamma cells (31 +/- 15%) and a decrease in Tmu cells (38 +/- 11%) were observed if compared with normal controls (16 +/- 6% for T gamma and 51 +/- 13% for Tmu). In half of the patients, however, these values were normal. T gamma cells were highest in the splenectomized patients and in the 15 non-splenectomized patients T gamma cells were higher in those with active disease. Patients with stable disease or in remission had values close to normal. The T colony-forming capacity of unseparated and enriched T lymphocytes was normal regardless of the T cell subset distribution and clinical stage of the disease. These findings suggest that in HCL, unlike B cell chronic lymphocytic leukemia, the imbalance in Tmu/T gamma ratio does not result in an impairment of the in vitro T colony-forming capacity.

Animals↗
PubMedDate not supplied

Expanding the nursing profession.

this paper explores the political, economic and demographic developments which are shaping new nursing practices throughout the world. The authors observe that these developments are generally seen to challenge traditional models of nursing and encourage the role of sub-professional support workers.

Humans↗
PubMedDate not supplied

Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase.

BACKGROUND: Despite the fact that granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are increasingly used in clinical practice, little is known of their endogenous production, especially in myeloproliferative disorders such as chronic myelogenous leukemia (CML). METHODS: In order to define serum levels of GM-CSF and G-CSF in subjects affected by CML, the sera of 17 patients with CML in chronic phase treated either with hydroxyurea or interferon-alpha were tested by specific enzyme immunoassays. Fifteen age- and sex-matched healthy volunteers were used as normal controls. RESULTS: Eight out of the 17 patients (44%) with CML showed detectable (> 3 pg/mL) serum levels of GM-CSF (range 3.9-55 pg/mL). Detectable levels (> 50 pg/mL) of G-CSF were observed in 9 of these patients (52%) (range 150-2,830 pg/mL). On the contrary, among the normal controls only one had detectable GM-CSF concentrations, and none had detectable G-CSF concentrations. The highest concentrations of both GM-CSF and G-CSF were seen in patients with the highest white blood cell counts, although a linear correlation between the levels of these growth factors and the number of circulating leukocytes was not demonstrated. CONCLUSIONS: Our data indicate that significant amounts of both endogenous GM-CSF and G-CSF are detectable in the serum of a substantial percentage of patients with CML in chronic phase. The pathophysiological meaning of this finding remains to be determined.

Adult↗
PubMedDate not supplied

Mixed lymphocyte reactions evaluated by means of bromodeoxyuridine incorporation.

The mixed lymphocyte reactions are usually performed by the uptake of 3H thymidine (3H TdR) in the study of histocompatibility for allogeneic bone marrow transplantation. Bromodeoxyuridine (BrdUrd), an analogue of thymidine, can be used as an alternative marker of proliferation. In this study we compared the evaluation of the proliferative activity of alloreactive lymphocytes in MLR by 3H TdR and BrdUrd incorporation in flow cytometry. The results show that BrdUrd is able to recognize proliferative activity at least 24-48 hours before 3H TdR, and allows discrimination of proliferation of a few cells despite its proximity to the autologous controls. However, the large quantity of cells needed for every combination is presently a disadvantage of the method.

Bromodeoxyuridine↗
PubMedDate not supplied

[Effects of cigarette smoking on blood and alveolar air levels of benzene].

Benzene was measured in blood and alveolar air of a group of 168 subjects, consisting of 34 chemical industry workers exposed to benzene and 134 definitely not occupationally exposed to benzene. A gas chromatographic method was used with mass spectrometry and cryogenic trap. The results of the biological measurements were compared with the environmental levels of benzene in the room where samples were taken and at the worksite during the previous day's shift. All environmental air samples showed measurable levels of benzene, which agrees with the observations of many authors, according to which benzene is a common pollutant also of the living and external environments. Benzene in blood measured on morning samples was correlated with the previous day's exposure. In the group of non-exposed, both blood and alveolar concentrations of benzene were significantly higher in the 68 smokers than in the 66 non-smokers and the biological levels of benzene were inversely correlated with the time that had elapsed since the last cigarette smoked. In the chemical workers, the high biological levels of benzene due to occupational exposure largely exceeded the variations in concentration due to cigarette smoking and cancelled out the differences between smokers and non-smokers. It can therefore be assumed that smoking was not influential and did not interfere with the interpretation of the results in the occupationally exposed workers. Lastly, cigarette smoking, as a cyclical and additional factors of exposure, seems to be responsible for the disturbance in the relationships between biological benzene levels and ubiquitous environmental pollution, a relationship that was only observable in non-smoking subjects not occupationally exposed, but not in the group of smokers.

Benzene↗
PubMedDate not supplied

Evaluation of LAK-mediated tumor cell killing in a plasma clot clonogenic assay.

An assay based on the inhibition of the cloning capacity in a plasma clot semisolid medium assay has been used to test the sensitivity of the Raji cell line to lymphokine-activated killer (LAK) cells. This method overcomes some limitations intrinsic to the widely employed 51Cr release assay and always shows a higher degree of sensitivity. No inhibition of colony growth was found when the effector cells were plated without prior pre-incubation with interleukin 2 or with the addition of the medium derived from the LAK cells. Though more time-consuming than the classic 51Cr release assay, this technique does not require radioactive material. This test may be suitable for a more precise evaluation of LAK activity and for the study of the mechanisms involved in cell killing.

Burkitt Lymphoma↗